[go: up one dir, main page]

MA27565A1 - Derives de 4-tetrazolyl-4-phenylpiperidine utilises pour le traitement de la douleur - Google Patents

Derives de 4-tetrazolyl-4-phenylpiperidine utilises pour le traitement de la douleur

Info

Publication number
MA27565A1
MA27565A1 MA28335A MA28335A MA27565A1 MA 27565 A1 MA27565 A1 MA 27565A1 MA 28335 A MA28335 A MA 28335A MA 28335 A MA28335 A MA 28335A MA 27565 A1 MA27565 A1 MA 27565A1
Authority
MA
Morocco
Prior art keywords
tetrazolyl
treatment
methods
phenylpiperidine
pain
Prior art date
Application number
MA28335A
Other languages
English (en)
Inventor
Zhengming Chen
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of MA27565A1 publication Critical patent/MA27565A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des composés de 4-tétrazolyl-4-phénylpipéridine, des compositions contenant une quantité efficace d'un composé de 4-tétrazolyl-4-phénylpipéridine, ainsi que des procédés pour traiter et prévenir la douleur ou la diarrhée chez un animal. Lesdits procédés consistent à administrer à un animal, nécessitant un tel traitement, une quantité efficace d'un composé de 4-tétrazolyl-4-phénylpipéridine. L'invention concerne également des procédés pour stimuler la fonction de récepteurs opioïdes dans une cellule, lesdits procédés consistant à mettre en contact une cellule pouvant exprimer un récepteur opioïde avec une quantité efficace d'un composé de 4-tétrazolyl-4-phénylpipéridine.
MA28335A 2002-11-18 2005-06-13 Derives de 4-tetrazolyl-4-phenylpiperidine utilises pour le traitement de la douleur MA27565A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42738102P 2002-11-18 2002-11-18
US46027803P 2003-04-03 2003-04-03
US48848803P 2003-07-17 2003-07-17
US10/714,066 US7202259B2 (en) 2002-11-18 2003-11-13 Therapeutic agents useful for treating pain

Publications (1)

Publication Number Publication Date
MA27565A1 true MA27565A1 (fr) 2005-10-03

Family

ID=32777221

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28335A MA27565A1 (fr) 2002-11-18 2005-06-13 Derives de 4-tetrazolyl-4-phenylpiperidine utilises pour le traitement de la douleur

Country Status (36)

Country Link
US (3) US7202259B2 (fr)
EP (2) EP1562932B9 (fr)
JP (2) JP4601429B2 (fr)
KR (1) KR20050115221A (fr)
CN (2) CN101648941A (fr)
AP (1) AP2210A (fr)
AR (1) AR047008A1 (fr)
AT (2) ATE358674T1 (fr)
AU (2) AU2003294313B2 (fr)
BR (1) BR0316305A (fr)
CA (1) CA2506242C (fr)
CO (1) CO5690588A2 (fr)
CR (2) CR7877A (fr)
CY (2) CY1107682T1 (fr)
DE (2) DE60322451D1 (fr)
DK (2) DK1803718T3 (fr)
EA (1) EA008621B1 (fr)
EC (1) ECSP055840A (fr)
ES (2) ES2312150T3 (fr)
GE (1) GEP20084539B (fr)
IL (1) IL209352A0 (fr)
IS (2) IS2720B (fr)
MA (1) MA27565A1 (fr)
ME (1) MEP48108A (fr)
MX (1) MXPA05004669A (fr)
MY (1) MY135647A (fr)
NI (1) NI200500087A (fr)
NO (1) NO20052894L (fr)
NZ (2) NZ540068A (fr)
OA (1) OA13010A (fr)
PT (2) PT1562932E (fr)
RS (1) RS51047B (fr)
SG (1) SG165998A1 (fr)
SI (2) SI1803718T1 (fr)
TW (2) TW200819436A (fr)
WO (1) WO2004046132A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202259B2 (en) * 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
ME00276B (fr) 2003-04-30 2011-05-10 Purdue Pharma Lp Forme posologique transdermique a fermeture inviolable
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
CA2552087C (fr) 2004-01-30 2011-01-25 Euro-Celtique S.A. Procedes d'elaboration de composes de 4-tetrazolyl-4-phenylpiperidine
SE0401656D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
WO2007057229A1 (fr) * 2005-11-21 2007-05-24 Purdue Pharma L.P. Composes a base de 4-oxadiazolyl-piperidine et utilisation de ceux-ci
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US8771693B2 (en) 2009-10-27 2014-07-08 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
WO2012038813A1 (fr) 2010-09-21 2012-03-29 Purdue Pharma L.P. Analogues de buprénorphine
CN102648915B (zh) * 2011-02-28 2015-04-15 鲁南制药集团股份有限公司 一种治疗或预防神经病理性疼痛的药物组合物
US10487114B2 (en) 2011-04-27 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
US10138207B2 (en) 2012-11-09 2018-11-27 Purdue Pharma, L.P. Benzomorphan analogs and the use thereof
US9175000B2 (en) 2012-12-07 2015-11-03 Purdue Pharma L.P. Buprenorphine analogs
EP2931726B1 (fr) 2012-12-14 2017-01-25 Purdue Pharma LP Morphinanes spirocycliques et leur utilisation
US8980906B2 (en) 2012-12-14 2015-03-17 Purdue Pharma L.P. Pyridonemorphinan analogs and biological activity on opioid receptors
US9056836B2 (en) 2013-01-31 2015-06-16 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
WO2015097548A1 (fr) 2013-12-26 2015-07-02 Purdue Pharma L.P. Analogues 7-bêta-alkyle d'orvinols
US9994571B2 (en) 2013-12-26 2018-06-12 Purdue Pharma L.P. 10-substituted morphinan hydantoins
US9340542B2 (en) 2013-12-26 2016-05-17 Purdue Pharma L.P. Propellane-based compounds and the use thereof
CA2934913A1 (fr) 2013-12-26 2015-07-02 Purdue Pharma L.P. Morphinanes a cycle contracte et leur utilisation
US9862726B2 (en) 2013-12-26 2018-01-09 Purdue Pharma L.P. Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
EP3086790A4 (fr) 2013-12-27 2017-07-19 Purdue Pharma LP Analogues de la morphinane 6-substitués et 7-substitués, et leurs utilisations
CA2950567A1 (fr) 2014-05-27 2015-12-03 Purdue Pharma L.P. Morphinanes spirocycliques et utilisation associee
MA40171A (fr) 2014-06-13 2017-04-19 Purdue Pharma Lp Dérivés d'azamophinan et leur utilisation
MA41125A (fr) 2014-12-05 2017-10-10 Purdue Pharma Lp Dérivés de 6.7-cyclomorphinane et leur utilisation
US11529340B2 (en) 2016-03-22 2022-12-20 Regents Of The University Of Minnesota Combination for treating pain
FI3490560T3 (fi) 2016-07-29 2025-02-27 Janssen Pharmaceutica Nv Niraparibi käytettäväksi eturauhassyövän hoitomenetelmässä
US10745402B2 (en) 2017-01-02 2020-08-18 Purdue Pharma L.P. Morphinan derivatives and use thereof
EP4340837A4 (fr) * 2021-05-21 2025-04-09 Purdue Pharma L.P. Méthodes de traitement du syndrome de la cystite interstitielle/douleur de la vessie
WO2023250190A1 (fr) * 2022-06-24 2023-12-28 Purdue Pharma L.P. Méthodes de traitement ou de prévention du syndrome de la vessie hyperactive

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
BE775611A (fr) 1970-11-24 1972-03-16 Synthelabo Derives de la (diphenyl-3,3 propyl-1)-1 piperidine, leur preparation etles medicaments qui en contiennent
US4076717A (en) * 1971-12-15 1978-02-28 G. D. Searle & Co. Derivatives of 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylic acid
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
DK162087D0 (da) * 1987-03-31 1987-03-31 Ferrosan As Piperidinforbindelser, deres fremstilling og anvendelse
US4831192A (en) * 1987-12-31 1989-05-16 Boc, Inc. Methods of preparing 4-heteropentacyclic-4-(N-phenyl)amido) piperidine derivatives and intermediate compounds
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5449989A (en) 1992-07-31 1995-09-12 Correa; Paulo N. Energy conversion system
US5606037A (en) 1992-11-09 1997-02-25 Biochem Pharma Inc. Processes antineoplastic heteronaphthoquinones
US5736523A (en) 1992-11-09 1998-04-07 Biochem Pharma Inc. Antineoplastic heteronapthoquinones
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5849737A (en) 1995-04-14 1998-12-15 The Regents Of The University Of California Compositions and methods for treating pain
US6166085A (en) 1995-04-14 2000-12-26 The Regents Of The University Of California Method of producing analgesia
JPH11507670A (ja) 1995-06-12 1999-07-06 ジー．ディー．サール アンド カンパニー シクロオキシゲナーゼ−２インヒビターと５−リポキシゲナーゼインヒビターの組合せによる炎症と炎症関連疾患の治療
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US6573282B1 (en) 1995-09-12 2003-06-03 Adolor Corporation Peripherally active anti-hyperalgesic opiates
WO1997024325A1 (fr) 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DERIVES DE DIPHENYLMETHANE UTILISES COMME ANTAGONISTES DU RECEPTEUR MIP-1α/RANTES
US6221888B1 (en) 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
ATE200781T1 (de) * 1997-06-10 2001-05-15 Synthon Bv 4-phenylpiperidin-derivate
AU3254499A (en) 1998-03-06 1999-09-20 Janssen Pharmaceutica N.V. Glycine transport inhibitors
US6423519B1 (en) * 1998-07-15 2002-07-23 Gpc Biotech Inc. Compositions and methods for inhibiting fungal growth
PE20001420A1 (es) 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
US7217714B1 (en) 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
KR100709497B1 (ko) 1999-03-12 2007-04-20 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 소염제로서 유용한 화합물 및 이의 제조방법
EP1219294A4 (fr) 1999-09-20 2005-01-26 Antagonistes de l'hormone de concentration de la melanine
CA2324330A1 (fr) 1999-11-08 2001-05-08 Ssp Co., Ltd. Derives de la 4-hydroxy-4-phenylpiperidine et produits pharmaceutiques a base de ceux-ci
DE60022226D1 (de) 1999-12-06 2005-09-29 Euro Celtique Sa Benzimidazolverbindungen die nociceptinrezeptoraffinität haben
US6486142B2 (en) 1999-12-22 2002-11-26 Merck Frosst Canada & Co. Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
US6703525B2 (en) 2000-02-16 2004-03-09 Boehringer Ingelheim Pharmaceuticals, Inc. Sulfonamide intermediates and methods of producing same
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
AU2001242744B2 (en) * 2000-03-24 2005-07-21 Meiji Seika Kaisha Ltd Diphenylalkylamine derivatives useful as opioid delta receptor ligands
US6544981B2 (en) 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
CA2424979A1 (fr) 2000-10-12 2003-04-04 Ssp Co., Ltd. Derives 2,2-diphenylbutanamide et agents pharmaceutiques contenant ces composes
AU2002226000A1 (en) 2000-11-13 2002-05-21 Atrix Laboratories, Inc. Injectable sustained release delivery system with loperamide
US7202259B2 (en) * 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
CA2552087C (fr) 2004-01-30 2011-01-25 Euro-Celtique S.A. Procedes d'elaboration de composes de 4-tetrazolyl-4-phenylpiperidine

Also Published As

Publication number Publication date
JP2010163452A (ja) 2010-07-29
AU2003294313B2 (en) 2010-08-26
AR047008A1 (es) 2006-01-04
CA2506242A1 (fr) 2004-06-03
DK1803718T3 (da) 2008-10-27
CN101648941A (zh) 2010-02-17
TW200418828A (en) 2004-10-01
SI1803718T1 (sl) 2008-12-31
DE60313021D1 (de) 2007-05-16
NI200500087A (es) 2007-07-24
JP4601429B2 (ja) 2010-12-22
AU2010246411A1 (en) 2010-12-16
DE60313021T2 (de) 2007-12-13
ECSP055840A (es) 2005-08-11
ES2285235T3 (es) 2007-11-16
EP1562932B9 (fr) 2007-09-12
IL209352A0 (en) 2011-01-31
PT1803718E (pt) 2008-09-26
TW200819436A (en) 2008-05-01
EA008621B1 (ru) 2007-06-29
DK1562932T3 (da) 2007-08-13
EA200500726A1 (ru) 2005-10-27
SG165998A1 (en) 2010-11-29
EP1562932A1 (fr) 2005-08-17
RS20050375A (sr) 2007-11-15
CA2506242C (fr) 2011-07-05
CO5690588A2 (es) 2006-10-31
RS51047B (sr) 2010-10-31
AU2003294313A1 (en) 2004-06-15
EP1562932B1 (fr) 2007-04-04
EP1803718B1 (fr) 2008-07-23
MY135647A (en) 2008-06-30
MXPA05004669A (es) 2005-06-08
US20100069437A1 (en) 2010-03-18
CN100567288C (zh) 2009-12-09
AP2005003297A0 (en) 2005-06-30
ES2312150T3 (es) 2009-02-16
IS7812A (is) 2005-04-19
HK1086829A1 (zh) 2006-09-29
NO20052894D0 (no) 2005-06-14
WO2004046132A1 (fr) 2004-06-03
US8026254B2 (en) 2011-09-27
US20070179141A1 (en) 2007-08-02
NZ572685A (en) 2010-06-25
NZ540068A (en) 2007-07-27
MEP48108A (en) 2011-02-10
OA13010A (en) 2006-11-10
SI1562932T1 (sl) 2007-08-31
CR11037A (es) 2009-10-29
GEP20084539B (en) 2008-11-25
ATE358674T1 (de) 2007-04-15
IS8913A (is) 2010-07-21
CR7877A (es) 2005-11-30
CN1711256A (zh) 2005-12-21
US7202259B2 (en) 2007-04-10
KR20050115221A (ko) 2005-12-07
DE60322451D1 (de) 2008-09-04
PT1562932E (pt) 2007-07-02
TWI343917B (en) 2011-06-21
US7687518B2 (en) 2010-03-30
US20040152689A1 (en) 2004-08-05
AP2210A (en) 2011-02-25
CY1108422T1 (el) 2014-04-09
EP1803718A1 (fr) 2007-07-04
ATE402167T1 (de) 2008-08-15
CY1107682T1 (el) 2013-04-18
NO20052894L (no) 2005-06-14
JP2006525944A (ja) 2006-11-16
BR0316305A (pt) 2005-09-27
IS2720B (is) 2011-02-15

Similar Documents

Publication Publication Date Title
MA27565A1 (fr) Derives de 4-tetrazolyl-4-phenylpiperidine utilises pour le traitement de la douleur
MA32684B1 (fr) Dérivés de picolinamide en tant qu'inhibiteurs de kinase
MA28681B1 (fr) 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines
MA29915B1 (fr) Benzimidazoles substitues utilises en tant qu'inhibiteurs de kinases
MA28680B1 (fr) 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines
TN2009000138A1 (fr) Biaryl-ether-urees
MXPA04006280A (es) Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
ATE501722T1 (de) Therapeutische behandlung androgenrezeptorbedingter leiden
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
EA200100203A1 (ru) Производные 4,4-биарилпиперидина с активностью в отношении опиоидных рецепторов
MA32232B1 (fr) Nouveaux compoés hétérocycliques et leurs utilisations
MA30340B1 (fr) Nouveaux composes
EA200500392A1 (ru) Производные пиримидина и их применение в качестве модуляторов св2
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
EA200501504A1 (ru) Лиганды каннабиноидных рецепторов и их применение
MXPA05011166A (es) Antagonistas del receptor del peptido relacionado con el gen de la calcitonina.
BRPI0307355C1 (pt) composto de 2,4-pirimidinodiamina, e, composição farmacêutica compreendendo o mesmo
DK1461318T3 (da) Tetrahydroquinolinanaloge som muscariniske agonister
MA30720B1 (fr) Analogues de 2-phenoxypyrimidinone
MA30392B1 (fr) Composes organiques et leurs utilisations
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
EA200200132A1 (ru) СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА iGluRДЛЯ ЛЕЧЕНИЯ МИГРЕНИ
DE69935670D1 (de) Behandlung von dyskinesie durch mu-selektive opioidantagonisten
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
TW200624430A (en) 4-(heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists